New Novo Nordisk AI hub for drug discovery to open in London, UK
.png)
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations.
The hub will be situated in the Kings’ Cross Knowledge Quarter among world-leading science institutions and companies including AstraZeneca, GSK, the Wellcome Trust, and the Francis Crick Institute. Additionally, Novo Nordisk will build a new digital innovation hub that will host 40 employees from its current R&D and IT divisions.
A spokesperson for Novo Nordisk stated: “[The new facility] will accelerate innovation and collaboration to create and supply AI in the discovery and development of new potential drug candidates... it will represent a vibrant and diverse AI research ecosystem across fields including AI, data science, and engineering.” The AI research hub will also align with Novo Nordisk’s company aim to digitise processes across its business. The company stated that AI is already beginning to contribute to the research and development of new medicinal products. “[The hub will allow Novo Nordisk] to better collaborate with leading research institutions, big tech, and innovative start-ups and attract top talent,” Novo Nordisk’s spokesperson commented.
Prior to this announcement, the company recently entered into a collaboration with Valo Health to discover and develop novel treatments for cardiometabolic diseases using AI. Novo Nordisk’s London AI hub will also align with the UK’s goal to position itself as an international hub for AI. The country has launched various initiatives such as a new AI Safety Institute last November.
Source: Novo Nordisk to open new AI hub in UK for drug discovery [Accessed January 4, 2023] https://pharmatimes.com/news/novo-nordisk-to-open-new-ai-hub-in-uk-for-drug-discovery/
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance